P2097 - BRCA Mutations and Pancreatic Cancer: A Systematic Review and Meta-Analysis

Saurabh Chandan, MD¹, Smit S. Deliwala, MD², Antonio Facciorusso, MD, PhD³, Babu Mohan, MD⁴, Gursimran S. Kochhar, MD^5
1Creighton University School of Medicine, Omaha, NE; ²Michigan State University at Hurley Medical Center, Flint, MI; ³University of Foggia, Foggia, Puglia, Italy; ⁴University of Utah School of Medicine, Salt Lake City, UT; ⁵Allegheny Health Network, Pittsburgh, PA

Introduction: Pancreatic cancer (PC) carries a high mortality and is a leading cause of cancer death in the United States. The lifetime risk of PC in the population is 1.3%, approaching >5% in high-risk individuals such as those with mutations in BRCA genes. We conducted a systematic review and meta-analysis to assess the incidence of PC in BRCA-1 and BRCA-2 mutation carriers and estimate their incidence in patients with PC.

Methods: Major databases were searched until January 2021. A random-effects model was used to calculate the pooled rates and 95% confidence intervals (CI). Outcomes assessed were pooled proportion of BRCA-1 and BRCA -2 mutations in PC and incidence of PC in these mutation carriers.

Results: Nine studies reported on the incidence of BRCA-1 and BRCA-2 mutations in PC patients, whereas, thirteen studies reported the incidence of PC among BRCA mutation carriers. In 4462 patients with PC, 47 were found to have germline mutation in BRCA-1. Pooled proportion of mutation carriers was 1.1% (CI 0.3-1.8; I²=58.88%). Among 4426 patients with PC, 158 were found to have germline mutations in BRCA-2. Pooled proportion of mutation carriers was 7.9% (CI 4.8-11; I²=91.15%). Among 27,501 BRCA-1 mutation carriers, 121 developed PC. Pooled incidence ratio was 1.78 (CI 1.4-2.26; I²=13%). A total of 144 out of 16,256 BRCA-2 mutation carriers developed PC. Pooled incidence ratio was 3.98 (CI 1.26-12.52; I²=96%).

Discussion: Our results support the current recommendations of PC screening in high-risk individuals such as those with mutations in BRCA-1 and BRCA-2 genes.


Figure: Figure 1 - BRCA 2


Disclosures:
Saurabh Chandan indicated no relevant financial relationships.
Smit Deliwala indicated no relevant financial relationships.
Antonio Facciorusso indicated no relevant financial relationships.
Babu Mohan indicated no relevant financial relationships.
Gursimran Kochhar indicated no relevant financial relationships.


Saurabh Chandan, MD¹, Smit S. Deliwala, MD², Antonio Facciorusso, MD, PhD³, Babu Mohan, MD⁴, Gursimran S. Kochhar, MD⁵. P2097 - BRCA Mutations and Pancreatic Cancer: A Systematic Review and Meta-Analysis, ACG 2021 Annual Scientific Meeting Abstracts. Las Vegas, Nevada: American College of Gastroenterology.